Celebrating Decades of Dedication and Diversity in Healthcare Excellence RIYADH, Saudi Arabia, Jan. 23, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) recently hosted its Alumni Gathering in Riyadh. The event honoured several staff members who travelled from various parts of the world and have played a crucial role in shaping the hospital’s legacy of excellence. Some alumni have been part of KFSHRC since 1975, making this gathering a celebration of dedication, diversity ...

Nipocalimab Clinical Trial Results - Nipocalimab demonstrated a sustained reduction in autoantibody levels by up to 75% over 24 weeks in patients with generalized myasthenia gravis (gMG) [2] - The Phase 3 Vivacity-MG3 study met its primary endpoint, showing statistically significant improvement in MG-ADL score over 24 weeks [2] - Nipocalimab had a tolerable safety profile, with adverse events leading to discontinuation similar to placebo (5.1% vs 7.1%) [2] gMG Disease Overview - gMG is a chronic, rare autoantibody disease affecting an estimated 700,000 people worldwide and 56,000-123,000 in Europe [3] - The disease is characterized by fluctuating weakness of skeletal muscles, leading to symptoms like limb weakness, drooping eyelids, and breathing difficulties [9] - Approximately 10-15% of new MG cases are diagnosed in adolescents (12-17 years), with over 65% of pediatric cases in the EU occurring in girls [8] Nipocalimab Mechanism and Designations - Nipocalimab is an investigational FcRn blocker that reduces circulating IgG antibodies, including pathogenic autoantibodies [3] - The therapy has received multiple FDA designations including Priority Review for gMG, Breakthrough Therapy for Sjögren's disease, and Orphan Drug status for several conditions [6][15] - Johnson & Johnson submitted Marketing Authorization Applications to EMA and FDA in 2024 seeking approval for gMG treatment [5] Vivacity-MG3 Study Design - The Phase 3 study enrolled 199 gMG patients, with 153 being antibody positive, in a 24-week double-blind, placebo-controlled trial [10] - Patients received either nipocalimab plus standard of care (30 mg/kg IV loading dose followed by 15 mg/kg every two weeks) or placebo plus SOC [10] - The primary endpoint was mean change in MG-ADL score from baseline over Weeks 22-24 in antibody positive patients [10] Clinical Impact and Future Directions - Nipocalimab plus SOC demonstrated significantly greater reduction in MG-ADL response (≥2-point improvement) compared to placebo plus SOC (p=0.0213) [4] - A 1-2 point change in MG-ADL score can significantly impact patients' daily functioning, such as eating and breathing [4] - The publication of Phase 3 data in The Lancet Neurology and FDA Priority Review status mark important milestones in gMG treatment development [5]

Global Predictive Genetic Testing and Consumer Genomics Market Global Predictive Genetic Testing and Consumer Genomics Market Dublin, Jan. 23, 2025 (GLOBE NEWSWIRE) -- The "Predictive Genetic Testing and Consumer Genomics Market by Test, Application, by End-User, and By Region" report has been added to ResearchAndMarkets.com's offering.The global predictive genetic testing and consumer genomics market size was estimated to be USD 4.77 billion in 2023 and is expected to reach USD 17.16 billion by 2034 w ...

SINGAPORE, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Mediway Medical Centre is pleased to announce two significant achievements: the centre has surpassed 5,000 reviews on Google with an impressive 4.9-star rating, and it is launching a comprehensive Allergy Test Panel featuring 83 different allergens. The positive feedback from patients underscores the centre's commitment to providing exceptional healthcare services. The new Allergy Test Panel aims to assist individuals in identifying specific allergies, enabling t ...

SAN DIEGO, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Enphase Energy, Inc. (NASDAQ: ENPH) common stock between April 25, 2023 and October 22, 2024, both dates inclusive (the “Class Period”), have until Tuesday, February 11, 2025 to seek appointment as lead plaintiff of the Enphase Energy class action lawsuit. Captioned The Trustees of the Welfare and Pension Funds of Local 464A - Pension Fund v. Enphase Energy, Inc., No. 24-cv-09038 (N.D. Cal ...

Global Weight Loss Market Sees $590.13 Billion Valuation by 2033, Driven by Wellness Trends and Advancements in Technology & Personalized Solutions Weight Loss Market Weight Loss Market Dublin, Jan. 23, 2025 (GLOBE NEWSWIRE) -- The "Weight Loss Market Forecast by Type, Equipment Type, Service, Gender, Age Group, Countries and Company Analysis 2025-2033" report has been added to ResearchAndMarkets.com's offering.The weight loss market is expected to reach US$590.13 billion by 2033, growing from US$297.43 ...

Global Cellular Starting Materials Market Global Cellular Starting Materials Market Dublin, Jan. 23, 2025 (GLOBE NEWSWIRE) -- The "Cellular Starting Materials Market by Product, by Grade, by End-User, and By Region" report has been added to ResearchAndMarkets.com's offering.The global cellular starting materials market is estimated to be USD 1.45 billion in 2024 and is expected to reach USD 13.84 billion by 2035, with a CAGR of 22.77% during the forecast period 2025-2035 Growth in the market will be dr ...

U.S. Electric Vehicles Market U.S. Electric Vehicles Market Dublin, Jan. 23, 2025 (GLOBE NEWSWIRE) -- The "United States Electric Vehicles Market by Products, Range, Vehicle Type, Vehicle Class, and Company Analysis 2025-2033" report has been added to ResearchAndMarkets.com's offering.United States' Electric Vehicle market is expected to reach US$ 537.53 billion in 2033 from US$ 206.76 billion in 2024, with a CAGR of 11.20% from 2025 to 2033. A few of the drivers driving the market's expansion are incr ...

Market Overview - The neurological biomarkers market was valued at USD 9.5 billion in 2024 and is projected to grow at a CAGR of 10.9% from 2025 to 2034 [1] - The growth is driven by the rising prevalence of neurodegenerative disorders such as Alzheimer's and Parkinson's disease, primarily due to the aging population [1] Key Drivers - Increasing awareness among patients and healthcare providers about neurological disorders [1][13] - Advancements in genomics, proteomics, and imaging technologies enhancing early detection and diagnosis of neurological diseases [2] - Growing demand for personalized medicine, which leads to better patient outcomes [2] Market Segmentation By Product Type - Proteomic biomarkers led the market in 2024 with a value of USD 3.1 billion, driven by advancements in technologies like liquid chromatography–mass spectrometry (LC-MS/MS) and multiplex assays [4] - Other segments include genomic, metabolomic, imaging, and other biomarkers [4] By Disease Type - Alzheimer's disease held the largest market share of 45.5% in 2024, reflecting the urgent need for early diagnostic solutions [6] - Blood-based biomarkers are emerging as a less invasive and cost-effective alternative to traditional cerebrospinal fluid tests [6] By End Use - Hospitals and clinics dominated the market in 2024 and are projected to reach USD 11 billion by 2034 [7] - These facilities are increasingly adopting non-invasive biomarker diagnostics to improve patient outcomes through personalized care [7] Regional Insights - North America, particularly the U.S., held a significant market share in 2024, valued at USD 3.7 billion [8] - The region benefits from technological advancements, increased focus on precision medicine, and rising demand for personalized therapies [8] Industry Ecosystem - The industry ecosystem is supported by government funding, research collaborations, and private sector involvement [7] - Key growth drivers include the increasing prevalence of neurological disorders, advancements in biomarker research, and the adoption of personalized medicine [13] Future Trends - The focus on precision medicine is expected to boost demand for proteomic biomarkers in both clinical settings and drug development [5] - Regulatory landscape, Porter's analysis, and PESTEL analysis are also shaping the future of the market [15] Major Players - Key companies in the market include Abbott Laboratories, ACOBIOM, Alseres Pharmaceuticals, Banyan Biomarkers, Bio-Rad Laboratories, DiaGenic ASA, Johnson & Johnson Services, Merck KGaA, QIAGEN, Quanterix, Rules-Based Medicine, and Thermo Fisher Scientific [9]

Smart Home Systems and Government Incentives & Sustainability Targets Driving Industry Growth at 17.58% CAGR European Smart Lighting Market European Smart Lighting Market Dublin, Jan. 23, 2025 (GLOBE NEWSWIRE) -- The "Europe Smart Lighting Market Forecast by Offering, Technology, Installation Type, Light Source, Application, End User, Country and Company Analysis 2025-2033" report has been added to ResearchAndMarkets.com's offering.Europe's smart lighting market valued at USD 3.54 billion in the year of ...